Tectonic Therapeutic, Inc.
TX2100
Hereditary Hemorrhagic Telangiectasia (HHT)
Resolved
156days ago
Advisory committee · Feb 1, 2026
What's at stake
An FDA advisory committee reviews TX2100 for Hereditary Hemorrhagic Telangiectasia (HHT) around Feb 1, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Hosted Key Opinion Leader (KOL) Webinar: In February 2026, Tectonic hosted a virtual KOL event featuring Hanny Al-Samkari, MD (Massachusetts General Hospital, Harvard Medical School), who joined Tectonic’s Chief Scientific Officer to discus”